UTH Stock Chart & Stats
€489.20
€9.70(2.86%)
At close: 4:00 PM EST
€489.20
€9.70(2.86%)
Day’s Range― - ―
52-Week Range€238.10 - €522.80
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
€19.65B
Enterprise Value€25.83K
Total Cash (Recent Filing)€2.15B
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)18.1
Beta0.42
Next Earnings
Aug 05, 2026EPS Estimate
6.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)29.27
Shares Outstanding42,446,730
10 Day Avg. Volume7
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio1.16
Price to Book (P/B)3.04
Price to Sales (P/S)6.78
P/FCF Ratio20.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€582.64Price Target Upside19.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)24.47
Revenue Forecast (FY)€2.84B
Bulls Say, Bears Say
Bulls Say
High Profitability MarginsSustained, very high margins reflect strong pricing power and a capital-light specialty-product mix. Durable profitability supports ongoing R&D, commercial investments and returns generation even if revenue growth lags, preserving strategic optionality for launches and pipeline funding.
Debt-Free, Conservative Balance SheetZero debt and sizeable equity provide strong financial flexibility to fund launches, M&A (e.g., biotech acquisitions), manufacturing scale-up and clinical programs without refinancing risk. This reduces liquidity stress and supports multi-year strategic execution.
Transformative Clinical/Regulatory CatalystsRobust pivotal data and successful IPF trials materially expand addressable markets and product indications. Positive outcomes plus planned filings create structurally higher long-term revenue potential and market share gains if regulatory paths proceed as expected.
Bears Say
Sharp Recent Revenue DeclineA large trailing‑twelve‑month revenue drop weakens topline durability and increases dependence on upcoming approvals and launches. If underlying demand or pricing pressures persist, margins and growth targets may be harder to sustain despite strong unit economics.
Volatile And Weaker Free Cash Flow TrendWhile absolute cash generation remains meaningful, recent FCF volatility reduces predictable funding for launches, reinvestment and shareholder returns. Persistent weakness could force tradeoffs among R&D, commercial expansion and potential M&A.
Regulatory & Safety Constraints On New FormulationsMultiple device/formulation filings need additional bridging work and FDA interactions, extending timelines and execution risk. Safety limitations for oral vasodilators in certain lung diseases could constrain uptake and commercial positioning, tempering market expansion assumptions.
United Therapeutics News
UTH FAQ
What was United Therapeutics Corp.’s price range in the past 12 months?
United Therapeutics Corp. lowest stock price was €238.10 and its highest was €522.80 in the past 12 months.
What is United Therapeutics Corp.’s market cap?
United Therapeutics Corp.’s market cap is €19.65B.
When is United Therapeutics Corp.’s upcoming earnings report date?
United Therapeutics Corp.’s upcoming earnings report date is Aug 05, 2026 which is in 9 days.
How were United Therapeutics Corp.’s earnings last quarter?
United Therapeutics Corp. released its earnings results on May 06, 2026. The company reported €5.112 earnings per share for the quarter, missing the consensus estimate of €6.146 by -€1.035.
Is United Therapeutics Corp. overvalued?
According to Wall Street analysts United Therapeutics Corp.’s price is currently Undervalued.
Does United Therapeutics Corp. pay dividends?
United Therapeutics Corp. does not currently pay dividends.
What is United Therapeutics Corp.’s EPS estimate?
United Therapeutics Corp.’s EPS estimate is 6.2.
How many shares outstanding does United Therapeutics Corp. have?
United Therapeutics Corp. has 42,446,730 shares outstanding.
What happened to United Therapeutics Corp.’s price movement after its last earnings report?
United Therapeutics Corp. reported an EPS of €5.112 in its last earnings report, missing expectations of €6.146. Following the earnings report the stock price went up 1.114%.
Which hedge fund is a major shareholder of United Therapeutics Corp.?
Currently, no hedge funds are holding shares in DE:UTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
United Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€582.64 (19.10% Upside)
€582.64 (19.10% Upside)
Blogger Sentiment
Bullish
DE:UTH Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €131.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
72.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.30%
Trailing 12-Months
Company Description
United Therapeutics Corp.
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
UTH Company Deck
UTH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong clinical and commercial momentum: major positive clinical readouts (ADVANCE OUTCOMES and TETON 1/2), concrete revenue figures ($782M total; $458M Tyvaso) and clear growth drivers (Tyvaso DPI adoption, ralinepag oral and inhaled programs, RALDPI moving into Phase I). Operational headwinds and several regulatory/development uncertainties were acknowledged but described as addressed or manageable. On balance, the highlights—particularly the transformative phase III results and multiple near-term regulatory milestones—substantially outweigh the quarter-specific operational issues and the normal regulatory risks associated with new-device/formulation filings.View all DE:UTH earnings summariesUTH Revenue Breakdown
53.01% Tyvaso
21.26% Remodulin
15.44% Orenitram
8.55% Unituxin
1.75% Other
UTH Stock 12 Month Forecast
Average Price Target
€582.64
▲(19.10% Upside)